Monoclonal antibodies, small molecules, and Vaccines in the treatment of breast cancer
Monoclonal antibodies, small molecules, and Vaccines in the treatment of breast cancer
复制标题
DOI：
10.1634/theoncologist.9-suppl_3-4
复制
发表时间：
2004-01-01
期刊：
影响因子：
5.8
通讯作者：
Esteva, FJ
中科院分区：
文献类型：
--
作者：
Esteva, FJ
人表皮生长因子受体（HER，ErbB）家族的受体被认为是重要的治疗靶点，并且各种类型的基于分子的小分子，包括单克隆抗体、蛋白酪氨酸激酶抑制剂和治疗性疫苗，正在开发作为转移性乳腺癌的潜在疗法。曲妥珠单抗（Herceptin（R）; Genentech，Inc.; South San弗朗西斯科，CA），第一个批准的HER-2（ErbB-2）过表达转移性乳腺癌的单克隆抗体，提供了靶向特异性受体产生临床益处的原理证明。其他单克隆抗体和小分子双蛋白酪氨酸激酶抑制剂作为转移性乳腺癌的治疗显示出很大的前景，但需要在临床试验中进行评价，以评估其益处。治疗性疫苗可能发挥作用，特别是在早期疾病中，但它们具有更大的局限性和研究设计问题，使其难以进行评估。最佳的联合治疗方案与各种新的方法，包括小分子靶向治疗需要开发，和人群最有可能受益于靶向治疗需要确定。
The human epidermal growth factor receptor (HER, ErbB) family of receptors is considered an important therapeutic target, and various types of molecularly based small molecules, including monoclonal antibodies, protein tyrosine kinase inhibitors, and therapeutic vaccines, are in development as potential therapies for metastatic breast cancer. Trastuzumab (Herceptin(R); Genentech, Inc.; South San Francisco, CA), the first approved monoclonal antibody for HER-2 (ErbB-2)-overexpressing metastatic breast cancer, provided the proof of principle that targeting specific receptors results in clinical benefit. Other monoclonal antibodies and the small molecule dual protein tyrosine kinase inhibitors show great promise as treatments for metastatic breast cancer but require evaluation in clinical trials to assess their benefits. Therapeutic vaccines may have a role, particularly in early-stage disease, but they are associated with greater limitations and study design issues that make their evaluation difficult. Optimum combination therapy regimens with a variety of novel approaches that incorporate small molecule targeted therapies need to be developed, and the population most likely to benefit from targeted therapies needs to be identified.